(Q33337071)

25 July 2017

title

Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma (English)

1 reference

25 July 2017

1 reference

A Gajra

1

1 reference

25 July 2017

S A Mehdi

2

1 reference

25 July 2017

J Kirshner

3

1 reference

25 July 2017

N Newman

4

1 reference

25 July 2017

S L Graziano

5

1 reference

25 July 2017

language of work or name

1 reference

1 May 2001

1 reference

25 July 2017

1 reference

25 July 2017

volume

32

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

189-196

1 reference

25 July 2017

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Chemotherapy of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900213-0

7 January 2021

10.1016/S0169-5002(00)00213-0

Identifiers

DOI

1 reference

25 July 2017

1 reference